Intertumor and intratumor NY-ESO-1 expression heterogeneity Is associated With promoter-specific and global DNA methylation status in ovarian cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3283-3290

  Woloszynska Read, Anna ^a   Mhawech Fauceglia, Paulette ^a   Yu, Jihnhee ^a   Odunsi, Kunle ^a   Karpf, Adam R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; NY ESO 1 ANTIGEN; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; BIOSYNTHESIS; CPG ISLAND; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 50349087907     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5279     Document Type: Article

References (32)

1. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
5. De Smet C, Lurquin C, Lethe B, Martelange V, BoonT. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-richpromoter. Mol Cell Biol 1999;19:7327-35.
6. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, BoonT. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A1996;93:7149-53.
7. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006;25:6975-85.
8. Loriot A, De Plaen E, BoonT, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006;281:10118-26.
9. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-49.
10. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class l/ll specific-ities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:12837-42.
11. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004;64:9167-71
12. Smiraglia DJ, Rush LJ, Fruhwald MC, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001;10:1413-9.
13. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY- ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006:95:1 -30.
14. Scanlan MJ, GureAO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188:22-32.
15. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076 - 83.
16. Colella S, Shen L, Baggerly KA, Issa JP, Kr -he R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50.
17. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 2005; 77:504-10.
18. 18.Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004:64:4472-80.
19. Lee L, Wang RF.Wang X, et al. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 1999;5:20-5.
20. Karpf AR, Lasek AW, RirieTO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyl- transferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol 2004;65:18-27.
21. De Smet C, Courtois SJ, Faraoni I, etal. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995:42: 282-90.
22. KangY, Hong JA, Chen GA, Nguyen DM. Schrump DS. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007;26: 4394-403.
23. Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998:58:1245-52.
24. Rastetter M, Schagdarsurengin U, Lahtz C, et al. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 2007;22:1005-15.
25. Ostler KR, Davis EM, Payne SL, et al. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 2007:26:5553 - 63
26. Kholmanskikh 0, Loriot A, Brasseur F, De Plaen E, De Smet C. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008:122:777-84.
27. Vatolin S, Abdullaev Z, Pack SD, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes Cancer Res 2005:65: 7751 -62.
28. Hong JA, Kang Y, Abdullaev Z. et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer- testis gene in lung cancer cells. Cancer Res 2005; 65:7763-74.
29. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007:7:21.
30. Schrump DS, Fischette MR. Nguyen DM. et al Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006:12: 5777-85.
31. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies Oncogene 2003:22:6484-8
32. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006:1 116 - 20